References
  1. Henry J, Smeyne R, Jang H, et al. Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries. Parkinsonism Relat Disord 2010;16:566–571.
  2. Pinto, L. H., and R. A. Lamb. Understanding the mechanism of action of the anti-influenza virus drug amantadine. Trends Microbiol. 1995;3:271.
  3. Roberto Cilia, Salvatore Bonvegna, Giulia Straccia, et al. Effects of COVID‐19 on Parkinson’s disease clinical features: a community‐based case‐control study. Mov Disord. 2020; 10.1002/mds.28170. doi: 10.1002/mds.28170 [Epub ahead of print] PMCID: PMC7280741
  4. Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020c). Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-2629. https://doi.org/10.1172/JCI137244.
  5. Nie, S., Zhao, X., Zhao, K., Zhang, Z., Zhang, Z., and Zhang, Z. (2020b). Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study. medRxiv. https://doi.org/10.1101/2020.03.24.20042283.
  6. Philip W. Tipton, Zbigniew K. Wszolek. What can Parkinson’s disease teach us about COVID-19? Neurologia i Neurochirurgia Polska Polish Journal of Neurology and Neurosurgery 202054;2:204–206.